Bruno, RS, Song, Y, Leonard, S W, Mustacich, DJ, Taylor, AW , Traber, MG, Ho, E (2007) Dietary zinc restriction in rats alters antioxidant status and increases plasma F2 isoprostanes. Journal of Nutritional Biochemistry, 18(8):509-518

Additional OSU HHS Author(s): Traber, Maret   

Myzak, MC, Tong, P, Dashwood, WM, Dashwood, RH, Ho, E (2007) Sulforaphane retards the growth of human PC-3 prostate cancer xenografts and inhibits HDAC activity in human subjects. Experimental Biology and Medics, 232(2):227-234 Trevisiol, CH, Turner, RT , Pfaff, JE, Hunter, JC, Menagh, PJ, Hardin, K, Ho, E, Iwaniec, UT (2007) Impaired Osteoinduction in a Rat Model for Chronic Alcohol Abuse. Bone, 41(2):175-180

Additional OSU HHS Author(s): Hardin, Karin    Turner, Russell   

Dashwood, RH, Myzak, MC, Ho, E (2006) Dietary HDAC inhibitors: Time to rethink weak ligands for cancer prevention. Carcinogenesis, 27(2):344-9 Ho, E. (2006). Dashwood, RH, Myzak, MC and Ho, E. (2006). Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis. 2006 Feb;27(2):344-9. Myzak, MC, Hardin, K, Dashwood, RH, Ho, E (2006) Sulforaphane Inhibits Histone Deacetylase Activity in BPH-1, LnCaP, and PC-3 Prostate Epithelial Cells. Carcinogenesis, 27(4):811-819

Additional OSU HHS Author(s): Hardin, Karin   

Myzak, MC, Ho, E, Dashwood, RD (2006) Dietary agents as histone deacetylase inhibitors. Molecular Carcinogenesis, 45(6):443-446 Myzak, MC, Orner, GA, Ho, E, Dashwood, RH (2006) Sulforaphane suppresses tumorigenesis in Apcmin mice via inhibition of histone deacetylase. The Federation of American Societies for Experimental Biology, 20(3):506-8

Ermilova, IP, Ermilov, VB, Fischer, KA, Levy, MA, Ho, E, Periera, C, Beckman, JS. (2005). Protection by dietary zinc in the ALS mutant G93A SOD Transgenic Mice. Neuroscience Letters, 379(1):42-6 Offer, T, Ho, E, Bruno, RS, Traber, MG, Kuypers, F, Ames, BN. (2005). A simple assay for frequency of chromosome breaks and loss (Micronuclei) by flow Cytometry of Human Reticulocytes. FASEB Journal, 19(3):485-7 Ohtsu, H, Ho, E, Huang, YS, Chaung, LT, Bray, T. (2005). Conjugated Linoleic Acid Modulates Proliferation and Activation of NFkB and AP1 in Prostate Cancer Cells. Nutrition Research, 25: 655-662

Additional OSU HHS Author(s): Bray, Tammy   

Ho, E. Phi Kappa Phi Emerging Scholar Award, 2007.

Ho, E. Junior Faculty Award. American Urological Association travel award $1000 to annual conference, 2005.

Ho, E, Principal Investigator (2007- 2012) Dietary HDAC inhibitors in prostate cancer prevention, National Institutes of Health-National Cancer Institute. $293,440 direct Turner, R, Principal Investigator, Iwaniec, U, Lotinun, S, Ho, H, Co-Investigators (2006-2011) Etiology and Treatment of Parathyroid Bone Disease, National Institutes of Health. $188,000

Additional OSU HHS Faculty: Turner, Russell    

Bray, TM, Ho, E, Co-Investigators (2005-2009) Diet, Endocrine-Immune Interactions & Prostate Cancer, National Institute of Health and National Cancer Institute. $205,000

Additional OSU HHS Faculty: Bray, Tammy    

Ho, E, Principal Investigator (2005- 2007) Zinc in age-related macular degeneration, Linus Pauling Institute Pilot Grant. $20,000 Ho, E, Principal Investigator (2005-2006) Serum carotenoids in insitu and invasive cervical cancer, Northwest Health Foundation. $3,969 Ho, E, Principal Investigator (2006-2007) Dietary inhibitors of histone deacetylase in prostate cancer prevention, Medical Research Foundation and Oregon Health and Science University. $30,000 Ho, E. Gene expression profiling in zinc deficiency. Principal Investigator, College of Health and Human Sciences pilot, $4,900, 2004-2005. Ho, E. Gene expression profiling with zinc supplementation. Principal Investigator, Oregon State University, General Research Fund, $10,000, 2004-2005. Ho, E. USDA-NRI-Zinc, gene expression & DNA damage. USDA-NRI grant- $375,000, 2005-2008. Ho, E. Zinc in prostate cancer. Principal Investigator, Northwest Health Foundation, $22,138, 2004-2006.